Correction: 2021 DORIS definition of remission in SLE: final recommendations from an international task force

van Vollenhoven RF, Bertsias G, Doria A, *et al.* 2021 DORIS definition of remission in SLE: final recommendations from an international task force. *Lupus Sci Med* 2021;8:e000538. doi: 10.1136/lupus-2021-000538

The authors want to alert the readers that a typographical error noticed in Box 1, has now been corrected. The final bullet point, referring to medications, was corrected from (prednisolone <5 mg/day) to (prednisolone $\leq$ 5 mg/day), as shown below.

Box 1 The 2021 DORIS definition of remission in SLE

- ▶ Clinical SLEDAI=0.
- ▶ Physician Global Assessment <0.5 (0–3).
 - Irrespective of serology.
 - The patient may be on antimalarials, low-dose glucocorticoids (prednisolone $\leq$ 5 mg/day), and/or stable immunosuppressives including biologics.

OPEN ACCESS

Open access This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: <http://creativecommons.org/licenses/by-nc/4.0/>.

Lupus Sci Med 2022;9:e000538corr1. doi:10.1136/lupus-2021-000538corr1